FDA-approved Abl/EGFR/PDGFR kinase inhibitors show potent efficacy against pandemic and seasonal influenza A virus infections of human lung explants

FDA-approved Abl/EGFR/PDGFR kinase inhibitors show potent efficacy against pandemic and seasonal influenza A virus infections of human lung explants

Summary: Influenza viruses (IVs) cause substantial global morbidity and mortality. Given the limited range of licensed antiviral drugs and their reduced efficacy due to resistance mutations, repurposing FDA-approved kinase inhibitors as fast-tracked host-targeted antivirals is an attractive strategy...

Full description

Bibliographic Details
Main Authors: Robert Meineke, Sonja Stelz, Maximilian Busch, Christopher Werlein, Mark Kühnel, Danny Jonigk, Guus F. Rimmelzwaan, Husni Elbahesh
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:iScience
Subjects:
Virology
Cell biology
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004223003863

Internet

http://www.sciencedirect.com/science/article/pii/S2589004223003863

Similar Items